Efficacy of Dual PD-1/PD-L1 and CTLA-4 Inhibitors in Advanced NSCLC: A Meta-Analysis

A meta-analysis of 10 randomized controlled trials comprising 6,369 patients evaluates dual immune checkpoint inhibitor therapy for advanced or metastatic non-small cell lung cancer. The dataset, authored by Tianfu Dai and last updated in May 2026, aggregates results on overall and progression-free survival from major medical databases. It includes subgroup analyses based on patient characteristics like cancer type, PD-L1 expression, tumor mutational burden, and metastasis sites.

Use Cases

• Compare overall survival (OS) and progression-free survival (PFS) hazard ratios between dual ICI therapy and control treatments.
• Identify patient subgroups (e.g., by PD-L1 TPS, TMB, smoking status) that benefit significantly from dual immunotherapy.
• Assess the efficacy of dual ICI therapy in specific metastatic contexts, such as patients with or without brain or bone metastases.

Strengths

• Analysis is based on 10 randomized controlled trials, a gold-standard study design.
• Includes data from 6,369 patients, providing a substantial sample size for meta-analysis.
• Reports specific hazard ratios with 95% confidence intervals for primary and secondary outcomes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 44.0 KB document file, suggesting limited raw data scope.

Provenance

Source

Systematic search of Cochrane Library, Embase, Web of Science, and PubMed.

Collection Method

Meta-analysis of randomized controlled trials.

Time Range

Trials from database inception to August 2025.

Freshness

Last updated 2026-05-11 05:31:03; freshness should be verified.